Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Cancer Vaccines01:30

Cancer Vaccines

1.4K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?

Clinical genitourinary cancer·2026
Same author

Novel Chitosan Bioink Derived from <i>Eurycantha calcarata</i> (Lucas, 1869) for 3D Bioprinting of Cell-Compatible Scaffolds.

ACS omega·2026
Same author

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Spontaneous Regression of Clear Cell Renal Cell Carcinoma Metastases or Immune Restoration?

Current oncology (Toronto, Ont.)·2026
Same author

Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Real-world efficacy and safety of immune checkpoint blockades in advanced urothelial carcinoma with histologic variant subtypes: the pembroblad study.

Cancer immunology, immunotherapy : CII·2026

Related Experiment Video

Updated: Apr 19, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K

[Pertuzumab and solid tumors: perspectives].

Philippe Barthélémy1, Julie Leblanc1, Frédérique Wendling1

  • 1Hôpital de Hautepierre, Hôpitaux universitaire de Strasbourg, Département d'oncologie et hématologie médicale, 1, avenue Molière, BP 49, 67200 Strasbourg, France.

Bulletin Du Cancer
|December 24, 2014
PubMed
Summary

Pertuzumab, a novel dimerization inhibitor, offers improved survival for HER2-positive breast cancer. This review explores its potential in other solid tumors beyond breast cancer.

Keywords:
cancercolongastricovarypertuzumabprostate

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.7K

Related Experiment Videos

Last Updated: Apr 19, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

4.2K
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

6.0K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

7.7K

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Trastuzumab was the sole anti-HER2 antibody for HER2-positive breast and gastric cancers for a decade.
  • Pertuzumab, a dimerization inhibitor, significantly improved overall survival in first-line HER2-positive metastatic breast cancer when added to docetaxel and trastuzumab.
  • Pertuzumab is also approved for neoadjuvant HER2-positive breast cancer treatment.

Purpose of the Study:

  • To review the biological rationale, preclinical data, and clinical trial results of pertuzumab.
  • To focus on the efficacy of pertuzumab in solid tumors excluding breast cancer.

Main Methods:

  • Review of existing literature on pertuzumab.
  • Analysis of preclinical studies and clinical trial data.
  • Focus on solid tumors outside of breast cancer indications.

Main Results:

  • Pertuzumab represents a new class of anti-HER2 therapy.
  • Demonstrated survival benefits in HER2-positive metastatic breast cancer.
  • Clinical development extends beyond breast cancer.

Conclusions:

  • Pertuzumab shows promise as a dimerization inhibitor in HER2-targeted therapy.
  • Further investigation is warranted for its use in various solid tumors.
  • This review consolidates evidence for pertuzumab's broader oncological applications.